Atigliflozin_product_DataBase

Bioactivity	Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus[1].
In Vivo	AVE2268 (1-300 mg/kg，口服) 会导致小鼠和大鼠的尿葡萄糖排泄 (UGE) 呈剂量依赖性增加[2]。AVE2268 (10-100 mg/kg，口服) 剂量依赖性地降低小鼠葡萄糖 (腹腔注射或口服) 给药后的血糖波动[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
CAS	647834-15-9
Formula	C18H22O7S
Molar Mass	382.43
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Schudok M, et al. The magic of small structure differences in a sodium-glucose cotransporter drug discovery project-14 C-labelled drug candidates in a key-differentiating study. J Labelled Comp Radiopharm. 2021 Feb;64(2):73-76. [2]. Bickel M, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.

PeptideDB